Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftriaxone is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, meningitis, gonorrhea, pelvic inflammatory disease, sepsis, and as prophylaxis before certain surgeries. It acts by inhibiting the synthesis of the bacterial cell wall through binding to penicillin-binding proteins (PBPs), leading to defective cell walls and bacterial death. Ceftriaxone is administered intravenously or intramuscularly due to poor oral bioavailability. Placebo refers to an inert substance with no therapeutic effect; in clinical trials "placebo + ceftriaxone" would refer to a combination arm where both are administered for comparison or blinding purposes[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone and placebo.